Pemigatinib 13.5 mg (Pemazyre) is a medication used for the treatment of cholangiocarcinoma (bile duct cancer) with FGFR2 genetic alterations. Pemigatinib is a selective fibroblast growth factor receptor (FGFR) inhibitor that targets FGFR2, which is involved in the growth and survival of cancer cells. It is marketed under the brand name Pemazyre.

Pemigatinib 13.5 mg (Pemazyre)

Product Overview: Pemigatinib 13.5 mg (Pemazyre) is a targeted therapy used for the treatment of cholangiocarcinoma (bile duct cancer) with FGFR2 genetic alterations. Pemigatinib is a selective FGFR inhibitor that works by blocking the activity of FGFR2, a protein involved in cancer cell proliferation and survival. By inhibiting this receptor, Pemazyre helps slow the progression of cancer, improving survival outcomes for patients with this genetic mutation.

Key Benefits:

• Targeted therapy specifically for FGFR2 fusion-positive cholangiocarcinoma.
• Reduces tumor growth and may improve overall survival in patients with advanced or metastatic disease.
• Oral medication for convenient at-home use, reducing the need for intravenous treatments.

Indications:

• Cholangiocarcinoma (Bile Duct Cancer) with FGFR2 genetic alterations, including FGFR2 fusions or rearrangements.
• Approved for advanced or metastatic cholangiocarcinoma in patients who have previously received treatment and have progressed.

Dosage:

• The recommended dose is 13.5 mg taken orally once daily for 14 consecutive days followed by a 7-day break.
• Dosage may vary based on patient condition, and adjustments may be made by a healthcare provider if needed.

Precautions:

• Monitor for side effects: Pemigatinib may cause eye problems, liver toxicity, or high phosphate levels. Regular monitoring is required during treatment.
• Liver function: Patients should have liver function tests before starting treatment and regularly during treatment.
• Eye problems: Pemigatinib can cause vision-related issues, including dry eye or other visual disturbances, so eye exams may be required.
• Not recommended for use during pregnancy or breastfeeding.

Common Side Effects:

• Fatigue
• Diarrhea
• Eye issues (e.g., dry eyes, blurred vision)
• Elevated liver enzymes
• Skin rash
• High phosphate levels
• Nausea

Packaging:

• Pemigatinib 13.5 mg (Pemazyre) tablets come in a convenient oral tablet form, packaged in [insert packaging type] for patient ease of use.

Important Notes:

• Follow the prescribed dosing schedule and consult your healthcare provider for any dose adjustments or missed doses.
• Regular monitoring of liver function, eye health, and phosphate levels is essential to manage potential side effects.
• Store in a cool, dry place, away from direct sunlight and out of reach of children.